Metastatic HER2 Positive Breast Cancer Market Expected to Expand at an Impressive Rate Owing to the Launch of the Therapies by Key Pharma Companies in the Domain

June 29 04:42 2021
Metastatic HER2 Positive Breast Cancer Market Expected to Expand at an Impressive Rate Owing to the Launch of the Therapies by Key Pharma Companies in the Domain

Delveinsight Business Research LLP

DelveInsight’s “Metastatic HER2 Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Metastatic HER2 Positive Breast Cancer Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

HER2-Positive Breast Cancer is a type of breast cancer in which breast cancer cells test shows positive status for a protein receptor called human epidermal growth factor receptor 2. The normal function of this protein is to control how a healthy breast cell grows, divides, and repairs itself.

But when there is a mutation in the gene that controls the HER2 protein, also known as erythroblastic oncogene B (ERBB2) gene, the body creates too many HER2 receptors, which results in uncontrollable breast cell growth and division. The most common signs of this indication are breast swelling, change in the shape of the breast, skin irritation or dimpling, pain in the breast, redness or thickness of the breast skin.

Diagnosis of HER2-positive breast cancer is made by following recommended tests, such as the IHC test, the FISH test, the SPOT-Light HER2 CISH, and the Inform HER2 Dual ISH tests. These tests use antibodies or DNA to stain the cancer cells.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market

The Metastatic HER2 Positive Breast Cancer Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Metastatic HER2 Positive Breast Cancer market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Metastatic HER2 Positive Breast Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Metastatic HER2 Positive Breast Cancer Market

Metastatic HER2 Positive Breast Cancer Market Key Facts

  • According to the American Institute for Cancer Research, there were over 2 million new cases of breast cancer in 2018 worldwide. The age-standardized rate of breast cancer in women in the United Kingdom alone is 93.6 per 100,000. And as per Breast Cancer Now, around 55,000 women and 370 men are diagnosed with breast cancer every year in the UK of which eight out of 10 cases of breast cancer are diagnosed in women aged 50 and over.

  • As per a study conducted by Howlader et al. titled “US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status”, among case-patients with known HR/HER2 status, 5240 (10.3%) were found to be HR-positive/HER2-positive and 2328 (4.6%) were HR−negaƟve/HER2-positive.

  • According to the American Cancer Society, about 17% of breast cancers overproduce the growth-promoting protein HER2. There are 5-year relative survival rates for women with all types of breast cancer: Stage 0 or Stage 1 (also known as localized or no metastatic): nearly 100%, Stage 2: 93%, Stage 3: 72%, Stage 4 (also known as metastatic): 22%.

Key Benefits of Metastatic HER2 Positive Breast Cancer Market Report

  • Metastatic HER2 Positive Breast Cancer market report provides an in-depth analysis of Metastatic HER2 Positive Breast Cancer Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Metastatic HER2 Positive Breast Cancer Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Metastatic HER2 Positive Breast Cancer current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Metastatic HER2 Positive Breast Cancer market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Metastatic HER2 Positive Breast Cancer Market

Metastatic HER2 Positive Breast Cancer Market Size is expected to increase during the forecast period owing to the launch of upcoming therapies. The therapies under development are focused on novel approaches that are expected to improve or treat the disease condition to a larger extent.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Metastatic HER2 Positive Breast Cancer market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Metastatic HER2 Positive Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

Metastatic HER2 Positive Breast Cancer Therapeutics market

The market comprises a variety of options for the treatment of HER-2 Positive Metastatic Breast Cancer. Treatment, which is mainly categorized into pharmacological and non-pharmacological therapies. Systemic therapies are generally prescribed by a medical oncologist. Common ways to give systemic therapies include an intravenous tube or can be given orally.

 Metastatic HER2 Positive Breast Cancer Epidemiology

The epidemiology section covers insights about the historical and current Metastatic HER2 Positive Breast Cancer patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Metastatic HER2 Positive Breast Cancer Epidemiology Segmentation

  • Total Incidence of Breast Cancer

  • Total Incidence of Metastatic Breast Cancer

  • Stage-specific Incidence of Breast Cancer

  • Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER+]

Metastatic HER2 Positive Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2 Positive Breast Cancer market or expected to get launched in the market during the study period. The analysis covers Metastatic HER2 Positive Breast Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Metastatic HER2 Positive Breast Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Metastatic HER2 Positive Breast Cancer market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Metastatic HER2 Positive Breast Cancer emerging therapies.

Metastatic HER2 Positive Breast Cancer Companies:

  • Kadcyla

  • MacroGenics

  • Roche

  • Genentech

  • Pfizer 

  • Seattle Genetics

  • Merck Sharp & Dohme

  • Eli Lilly and Company

  • Dizal Pharmaceuticals

  • Novartis Pharmaceuticals

  • Puma Biotechnology

And others.

Metastatic HER2 Positive Breast Cancer Therapies Covered in the report includes:

  • Margetuximab

  • Ibrance (Palbociclib)

  • Tecentriq (Atezolizumab)

  • Keytruda (Pembrolizumab)

  • Abemaciclib (LY2835219)

And many more. 

At present, there are many drugs in the pipeline and are under investigation in the late-development stages of the clinical trial, and due to their launch in upcoming years, there will be a positive increase in the HER2-Positive Metastatic Breast Cancer market during the market forecast period.

Table of Content

1. Key Insights

2. Executive Summary 

3. Metastatic HER2 Positive Breast Cancer Competitive Intelligence Analysis

4. Metastatic HER2 Positive Breast Cancer Market Overview at a Glance

5. Metastatic HER2 Positive Breast Cancer Disease Background and Overview

6. Metastatic HER2 Positive Breast Cancer Patient Journey

7. Metastatic HER2 Positive Breast Cancer Epidemiology and Patient Population

8. Metastatic HER2 Positive Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Metastatic HER2 Positive Breast Cancer Unmet Needs

10. Key Endpoints of Metastatic HER2 Positive Breast Cancer Treatment

11. Metastatic HER2 Positive Breast Cancer Marketed Products

12. Metastatic HER2 Positive Breast Cancer Emerging Therapies

13. Metastatic HER2 Positive Breast Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Metastatic HER2 Positive Breast Cancer Market Outlook (7 major markets)

16. Metastatic HER2 Positive Breast Cancer Access and Reimbursement Overview

17. KOL Views on the Metastatic HER2 Positive Breast Cancer Market.

18. Metastatic HER2 Positive Breast Cancer Market Drivers

19. Metastatic HER2 Positive Breast Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market

Latest Reports By DelveInsight
Metastatic HER2 Positive Breast Cancer Pipeline Insights
Metastatic HER2 positive breast cancer Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Metastatic HER2 positive breast cancer market.

Healthcare Blog By DelveInsight 
Key Companies in The Eye Disorders Treatment Market
Globally, some of the most common eye diseases include uncorrected refractive error (myopia, hyperopia, presbyopia, astigmatism), Age-Related Macular Degeneration, Cataract, Diabetic Retinopathy, Glaucoma, and many. To tackle the rising Eye Disorders some of the major global pharmaceutical companies in the Eye Disease market such as Novartis, Roche, Eyenovia, Allergan, Sun Pharma, and others are diligently involved in the therapeutics development to mitigate the treatment gap. To read more, visit: Most Common Eye Disorders and Key Companies

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author